About
A clinical research operations company, built for Indian conditions.
Dognosis Biosciences Pvt Ltd (DBPL) is a private limited company incorporated under the Companies Act, 2013. Our mandate is to build infrastructure that generalises across sponsors and screening modalities.
Why we exist
Operations is the missing layer.
Diagnostic technology in India advances at frontiers comparable to anywhere in the world. The field-level capability to deploy that technology at population scale — in non-tertiary settings, in regional languages, with quality systems robust enough for regulatory scrutiny — has not advanced at the same pace.
DBPL exists to build the missing operational stack. Our first use case is the hardest one available: asymptomatic multi-cancer screening using breath analysis, deployed at community level across diverse Indian geographies. The methodology required to make that work — from CRC training to sample integrity to participant retention — generalises to any modality that requires distributed, population-scale clinical operations.
Cancer is the entry point. Population screening for non-communicable diseases is the destination.
How we engage
A CRO model, ready for sponsor engagement.
Master agreement
Sponsors engage DBPL through a Clinical Services Agreement — a master contract under which individual Studies and Study Sites are activated through Work Orders. Signed once, scaled operationally without legal renegotiation.
Fixed-fee model
DBPL is paid on a fixed-fee basis per camp or per Study Site. The fee covers direct costs and a margin sufficient to sustain continued operations and reinvestment. Efficiency gains accrue to DBPL — and so does the motivation to invest in our own infrastructure.
Sponsor-agnostic by design
Our SOPs, software systems, training curricula, and aggregate operational data are designed from the outset to be portable. The architecture preserves the optionality to serve other sponsors without retrofitting our capabilities.
Board of directors
The people accountable for the operation.
DBPL is governed by a three-member board combining clinical practice, commercial leadership, and the founding scientific vision of the Dognosis group.
Dr Shashikant Kulgod
Director
A senior surgeon with decades of clinical practice in Karnataka, Dr Shashikant brings hands-on knowledge of hospital systems, surgical workflow, and patient-facing care delivery — the operational realities that any field-level screening programme must contend with.
Dr Sanjeev Kulgod
Director · Surgical Oncologist
Surgical Oncologist and Managing Director of RadOn Cancer Centre, Hubballi, with advanced training in breast and gastrointestinal cancers from leading institutes in the UK and the Netherlands. Over two decades of experience; pioneered breast-conserving and oncoplastic breast surgeries in Northern Karnataka, with a strong focus on GI, hepatobiliary, pancreatic, and head & neck cancers. An active academic contributor — presenting research internationally and leading major oncology conferences — championing precision cancer care in the region.
Akash Kulgod
Director
Founder of the Dognosis group and a UC Berkeley alumnus, Akash works at the intersection of olfactory diagnostics, machine learning, and population-scale cancer screening — the technology stack that DBPL operationalises in Indian field conditions.
Partners & sponsors
Anchored in a real operation, open to the next sponsor.
DBPL collaborates with multiple sponsors and technology providers — including its anchor sponsor relationship with Dognosis India Private Limited (DIPL) — to deliver validated screening modalities at population scale.
DIPL is DBPL's anchor client today. The two companies were incorporated alongside each other because the operational complexity of running population-scale screening in India required dedicated focus and a different organisational form than a research and development company. DBPL is a separate legal entity, structured as a CRO — not as a captive vehicle.
We welcome conversations with grant programmes, study sites, hospital systems, academic partners, and sponsors of clinical studies and population screening programmes in India.